Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines
Section snippets
Patient recruitment
The study was approved by the East Birmingham Research and Ethics Committee and written consent was obtained from all patients. This was a prospective, nonrandomized, nonblinded, parallel-group, observational study within the setting of a routine obesity hospital clinic. Patients were first given treatment (sibutramine or orlistat) as decided by the treating clinician and were then approached by the observing research doctor; those who consented were subsequently allocated into 1 of 2 groups
Effect of modest weight loss on adipocytokines and other metabolic parameters
After 6 months on sibutramine, the first group (Table 1) had a 5.4% weight loss (P = .0001) and waist circumference change of 3.6% (P = .002). Analysis revealed that the modest change of weight improved significantly insulin sensitivity (HOMA-S%) (P = .03), increased HDL-cholesterol by 13.8% (P = .01), decreased triglycerides by 9.4% (P = .02), and decreased CRP by 9.7% (P = ..03). Sibutramine increased systolic and diastolic blood pressures, but changes were not statistically significant (P >
Discussion
Weight loss is associated with favorable changes in cardiovascular risk factors.30 Even modest weight loss following lifestyle changes or medical treatment has beneficial effects on several cardiovascular risk factors.31 The present data, as previous studies, have demonstrated the different beneficial effects of sibutramine and orlistat on anthropometric and metabolic parameters after weight loss.10, 11, 32 Most obese patients receive medical treatment in obesity hospital clinics with the aim
References (37)
- et al.
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
Lancet
(1998) - et al.
Paradoxical decrease of an adipocyte-specific protein, adiponectin in obesity
Biochem Biophys Res Commun
(1999) - et al.
Resistin, central obesity, and type 2 diabetes
Lancet
(2002) - et al.
A cysteine rich adipose tissue-specific secretory factor inhibits adipocyte differentiation
J Biol Chem
(2001) - et al.
The perils of portliness
Diabetes
(2000) - et al.
Predictors of insulin sensitivity in type 2 diabetes
Diabetic Med
(2002) Medical hazards of obesity
Ann Intern Med
(1993)- et al.
The relation of markers of inflammation to the development of glucose disorders in the elderlyThe Cardiovascular Health Study
Diabetes
(2001) Beneficial health effects of modest weight loss
Int J Obes
(1992)Clinical Guideline on the Identification, Evaluation, and Treatment of Overweight and Obesity in AdultsThe Evidence Report
(1998)